Aminoacids and derivatives

<p>Applications Labelled cis-Tranexamic Acid (T714500). Antifibrinolytic agent; blocks lysine binding sites of plasminogen. Hemostatic.<br>References Andersson, et al.: Scand. J. Haematol. 2, 230 (1965), Melander, B., et al.: Acta Pharmacol. Toxicol., 22, 340 (1965), Bonnar, J., et al.: Br. Med. J., 313, 579 (1996), Dunn, C.J., et al.: Drugs, 57, 1005 (1999),<br></p>

<p>Applications Labelled Dapoxetine (D185700). Selective serotonin reuptake inhibitor (SSRI).<br>References Feret, B., et al.: Formulary, 40, 227 (2005),<br></p>

<p>Applications A Glycine (G615990) ester used as parakeratosis inhibitor and external composition for skin.<br>References Pucci, B., et al.: Eur. Polymer J., 26, 731 (1990),<br></p>

<p>Stability Hygroscopic<br>Applications Glycine 6-Ethylchenodeoxycholate can be used as reactant/reagent in synthetic preparation of bile acid analogs as FXR/TGR5 agonists.<br>References Or, Y., et al.: PCT Int. Appl., WO 2016073767 A1 20160512 (2016)<br></p>

<p>Applications O-Methyl-3,3',5,5'-tetraiodothyronamine is a derivative of p-Tyramine (T898500); an adrenergic.<br>References Brandacher, G., et al.: Curr. Drug Metab., 8, 289 (2007); Oresic, M., et al.: J. Exp. Med., 205, 2975 (2008)<br></p>

<p>Applications A labelled metabolite of Tryptophan (T947200).<br>References da Prada, M., et al.: Biochem. Pharmacol., 14, 1721 (1965), Curzon, G., et al.: Br. J. Pharmacol., 63, 627 (1978), Fukumori, R., et al.: J. Pharm. Pharmacol., 33, 586 (1981), Aasmoe, L., et al.: Biochem. Pharmacol., 57, 1067 (1999), Karamanakos, P., et al.: Pharmacol. Toxicol., 88, 106 (2001),<br></p>

<p>Trans-4-(aminomethyl)cyclohexanecarboxylic acid (AMCA) is a histamine antagonist that is used to treat bowel disease. It may also be useful for the treatment of other inflammatory diseases and as an anticoagulant. AMCA has been shown to be safe and effective for the prevention of postoperative bleeding in patients who are undergoing major surgery. This drug is a potent inhibitor of platelet aggregation, but does not affect the function of erythrocytes or leukocytes. AMCA inhibits platelet aggregation by blocking the binding of adenosine diphosphate (ADP) to its receptor on platelets, thus inhibiting ADP-mediated activation of phospholipase A2 and arachidonic acid release from membranes. An increase in blood levels of AMCA may lead to cardiac toxicity and bleeding events.</p>

<p>UNC0224 is a selective inhibitor of G9a with a Ki of 2.6 nM and IC50 of 15 nM. UNC0224 also potently inhibits GLP with assay-dependent IC50 values of 20-58 nM.</p>

<p>Carbidopa Impurity 2 is an impurity of carbidopa, a drug product that is used to treat Parkinson's disease. Carbidopa Impurity 2 is an analytical standard for the identification and quantification of carbidopa in biological samples. The natural form of this compound is unknown, but it has been synthesized using custom synthesis techniques. This compound was also used to develop a high purity HPLC standard and as a pharmacopoeia reference material.</p>

<p>Trans-trans-4,4'-Iminodimethylenedi(cyclohexanecarboxylic acid) is a hydrophobic particle that is soluble in water. It has an average particle diameter of 20 nm and a viscosity of 10 cps. Trans-trans-4,4'-Iminodimethylenedi(cyclohexanecarboxylic acid) is used in skin care products as a thickener and viscosity enhancer. It provides a silky feel to the skin and improves the skin's elasticity. This product also helps to protect the skin from UV radiation by forming a barrier on the surface of the skin. The natural polymer can be produced from glycerin or amide to produce different properties for different applications. Trans-trans-4,4'-Iminodimethylenedi(cyclohexanecarboxylic acid) is an amphoteric molecule that can react with both acidic</p>

<p>Carbidopa is an impurity of the drug L-DOPA, which is used as a treatment for Parkinson's disease. Carbidopa is a prodrug that is converted to L-DOPA by decarboxylase, an enzyme in the body. The conversion process can be inhibited by the presence of carbidopa impurity F (CIF), which binds to carboxamides and forms a stable complex with them. This prevents CIF from binding to decarboxylase and blocking its ability to convert carbidopa into L-DOPA. CIF has been shown to have anti-parkinsonian effects by reducing the severity of symptoms associated with Parkinson's disease such as muscular rigidity and tremors.</p>

<p>Dacisteine (N,S-Diacetyl-L-cysteine) is an inhibitor of New Delhi metallo-beta-lactamase-1 (NDM-1, IC50 = 1000 μM).</p>

<p>L-5-BromoTryptophan (5-BrW) is an analog of the tryptophan (Trp) effector and inhibits the gelation of hemoglobin S.</p>

<p>1,4-Dichloro 6-carboxytetramethylrhodamine is a rhodamine-class fluorescent dye with excitation/emission wavelengths of 541/568 nm.</p>